#CARTcells
LightNews LightNews
jdevos.bsky.social
VERY encouraging Phase 1 data for FT819: #iPSC-derived allogeneic #CARTcells show a promising safety profile and early signs of efficacy in lupus nephritis! Small cohorts and preliminary results, but an exciting step for off-the-shelf cell therapies.

buff.ly/xmBLhdj
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with…
buff.ly
October 27, 2026 at 1:06 PM
imtadvances.bsky.social
This review explores the bottom-up development of LGR5-targeting immunotherapeutics, showing how a highly specific α‑LGR5 antibody can be adapted into multiple modalities

📖 Read more: vist.ly/5pb85

#Immunotherapy #CancerResearch #CARTcells #PrecisionMedicine #OpenAccess
Wnt pathway illustration with modulation by RSPO showing gene expression changes.
October 21, 2026 at 10:59 AM
growhyzr.bsky.social
Could CAR-T therapy reset the immune system in lupus? Early studies show promising drug-free remission in some patients, but it’s not a proven cure.

#Lupus #CARTCells #Immunology #MedicalResearch #GroWhyzr
October 19, 2026 at 12:31 PM
imtadvances.bsky.social
Population modelling reveals key drivers of CAR T-cell dynamics in lymphoma patients, highlighting roles for lymphodepletion, tumour burden, and cytokines like IL-15/IL-7 🧬

🔗 vist.ly/5nbu9

#Immunotherapy #CARTcells #CancerResearch
Infographic with T-cell dynamic models, schematics, charts, and diagrams.
October 14, 2026 at 11:00 AM
jdevos.bsky.social
China tests CAR-T therapies faster than the rest of the world but regulatory changes could slow them down.
#CARTCells

buff.ly/Dioelh7
China now leads the world in trials for next-gen CAR-T therapies
China tests these therapies faster than the rest of the world but regulatory changes could slow them down.
buff.ly
September 28, 2026 at 11:37 AM
imtadvances.bsky.social
This review explores the bottom-up development of LGR5-targeting immunotherapeutics, showing how a highly specific α‑LGR5 antibody can be adapted into multiple modalities

📖 Read more: vist.ly/5ihju

#Immunotherapy #CancerResearch #CARTcells #PrecisionMedicine #OpenAccess
Wnt pathway illustration with modulation by RSPO showing gene expression changes.
September 15, 2026 at 12:20 PM
jdevos.bsky.social
Early but promising results with armored #CARTcells targeting glypican-3 and co-expressing IL-15 and IL-21 in pediatric hepatoblastoma. Step by step, CAR-T cells are beginning to make solid tumors addressable.

buff.ly/ZqJ8UbH
September 15, 2026 at 10:30 AM
currentmedscience.bsky.social
Why is #CD44v6 exciting in AML?

#Decitabine treatment increases CD44v6 expression on DNMT3A-mutant AML cells, improving recognition & targeting by #CARTcells. A promising step toward precision #Immunotherapy. #medsky

Read: doi.org/10.1007/s115...
#currentmedicalscience #Oncology
CD44v6 CAR-T Cells Target DNMT3A-Mutant AML: Synergistic Enhancement by Decitabine
September 10, 2026 at 12:30 PM
jem.org
Intravesical mesothelin-based #CARTcells targeting MUC16 effectively control #BladderCancer in preclinical models. From Parwiz Abrahimi, Renier Brentjens, Jedd Wolchok, Taha Merghoub et al.: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia
September 10, 2026 at 12:01 AM
jdevos.bsky.social
Deaths in a Novartis #CARTCells clinical trial for autoimmune diseases: follow-up.

www.fiercebiotech.com/biotech/nova...
UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies
Three deaths have forced Novartis to pause development of its CD19 CAR-T candidate in autoimmune diseases, just as Bristol Myers Squibb has halted a similar program due to immune-related adverse ev |…
www.fiercebiotech.com
September 4, 2026 at 9:25 AM
jdevos.bsky.social
⚠️ A reminder that #CARTcells expansion beyond cancer comes with real safety challenges. Novartis has paused 8 trials of its CAR-T therapy in autoimmune diseases after 3 patients died following severe immune reactions. A major setback for an otherwise highly promising field.
buff.ly/ApFP5Iy
September 1, 2026 at 11:45 AM
ipopi.bsky.social
During a recent trip to Brazil, Martine Pergent, President of IPOPI, had the opportunity to visit the brand-new CAR-T cell production unit at the Fernandes Figueira National Institute of Women’s, Children’s and Adolescents’ Health in Rio de Janeiro.

#IPOPI #AdvancedTherapies #CARTCells #Innovation
August 28, 2026 at 12:43 PM
chensun20.bsky.social
Excited to present my work on the CAR T cell immune synapse at #ICET2026 in Madison! So many inspiring talks and exciting advances in cryo-ET. Also loved touring the Midwest Center for Cryo-Electron Tomography! 🔬

#CryoET #CryoEM #ElectronTomography #StructuralBiology #CARTcells #teamtomo
August 17, 2026 at 7:31 PM
gmj-georgia.bsky.social
🔬 Breakthrough alert: USC researchers have developed a scalable stem cell method to produce cancer-fighting immune cells at scale. Preclinical stud…

#Cancerimmunotherapy #CARTcells #Cellmanufacturing #Precisionmedicine #Stemcelltherapy

#Cancerimmunotherapy #CARTcells #Cellmanufacturing #Precisi…
USC Unlocks Scalable Cancer-Fighting Immune Cell Production
🔬 Breakthrough alert: USC researchers have developed a scalable stem cell method to produce cancer-fighting immune cells at scale. Preclinical stud… #Cancerimmunotherapy #CARTcells #Cellmanufacturing #Precisionmedicine #Stemcelltherapy
news.gmj.ge
August 13, 2026 at 1:29 PM
jdevos.bsky.social
Anti-CD19 #CARTCells can persist up to 10 years after infusion in patients with lymphoid malignancies. In one patient CART cells comprised 1.2% of circulating T cells at 9y. Long-term persisting CART cells were predominant double-negative (CD4−CD8−), effector-memory-like phenotype.

buff.ly/FBYeuwR
August 12, 2026 at 5:06 PM
dpmp-unc.bsky.social
New work out of Brudno's lab "A Biomaterial Platform for T Cell-Specific Gene Delivery" doi.org/10.1016/j.ac...

#Science #Research #Immunology #CellTherapy #CARTCells
#Biomaterials #DrugDelivery #TCells
February 18, 2024 at 2:07 PM
thecancersurvivorsclub.com
Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatment! #TCSC #bmca #cartcells #cancertreatment #neuroblastoma #cancerfree

www.news-medical.net/news/2025021...
Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatment
A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children with neuroblastoma, with one patient remaining cancer-free for over 18 years.
www.news-medical.net
February 18, 2025 at 7:13 AM
isbt.bsky.social
Ideal for scientists, transfusion professionals, MDs, and MSc/PhD students.

www.isbtweb.org/events/isbt-...

#CARTcells #CellTherapy #TransfusionMedicine
ISBT Webinar: Let's talk CAR-T cells: cell heterogeneity, quality control and adverse events
www.isbtweb.org
March 3, 2026 at 1:30 PM
syedfakharshah.bsky.social
Please check out my article on T cells therapy.
www.linkedin.com/posts/syed-s...

#Cartcells #Cartcellstherapy #therapy #cancer #neuroblastoma #nervecancer #Carissawong #Clionarooney #newscientist #nationalcancerinstitute #cancergov #cancercare #cancerremission #remission
Syed Shah on LinkedIn: #cartcells #cartcellstherapy #therapy #cancer #neuroblastoma #nervecancer…
Record Cancer Remission A person has been cancer free for a record of 18 years . The CAR T cells therapy which is genetically modified. According to Kavin…
www.linkedin.com
March 5, 2025 at 11:00 PM
proteintech.bsky.social
Optimizing CAR-T Cell Expansion?

At present there is no consensus on which cytokine combination is the best for CAR T cell expansion. See below for points to consider when optimizing your protocols.

Try HumanKine® here: www.ptglab.com/products/gmp...

#CellTherapy #CARTcells
May 7, 2025 at 7:49 AM
castltrastondrs.medsky.network
This designed a CAR moiety by inserting CR2 & CR3 domains (CR2/3-CAR) of LDL receptor which is the viral receptor of oncolytic vesicular stomatitis virus (VSV) mutant (VSVΔ51), enabling specific loading of VSVΔ51 onto #CARTcells This approach potently enhanced the proliferation, metabolic fitness
September 14, 2025 at 5:18 AM
brainchildbio.bsky.social
Receiving two designations, RMAT and Breakthrough Therapy, from independent FDA reviews validates our positive #CARTcells clinical results and urgent need for a treatment for #DIPG. We're moving to initiate the pivotal trial by the end of 2025. #BrainChildTargetsCNSCancer
brainchildbio.com/press/
May 15, 2025 at 12:17 PM
brainchildbio.bsky.social
Breakthrough Therapy designation gives us the possibility to accelerate the development path for BCB-276 as a CAR T-cell therapy to potentially transform treatment of #DIPG, an incurable brain tumor. Our #CARTcells approach opens a new paradigm for other CNS brain tumors.
www.brainchildbio.com/press
April 22, 2025 at 12:44 PM
ipopi.bsky.social
The 10th #SEAPID anniversary meeting took place in Bangkok!
Co-hosted by IPOPI, Erasmus MC, Chulalongkorn Hospital & THCI, it focused on #CARTcells + their impact on #PID/#IEI.

Johan Prévot reflected on 10 years of collaboration w/ SEAPID — looking back + looking forward!

#GlobalHealth #IPOPI
April 8, 2025 at 10:16 AM
yahayayabo.bsky.social
Truly inspiring talk by Crystal Mackall on their journey in treating brain tumors with #CARTcells. #SNO2024
November 23, 2024 at 4:55 PM